Saba Capital Amends abrdn Life Sciences Investors Stake
Ticker: HQL · Form: SC 13D/A · Filed: Feb 7, 2024 · CIK: 884121
| Field | Detail |
|---|---|
| Company | Abrdn Life Sciences Investors (HQL) |
| Form Type | SC 13D/A |
| Filed Date | Feb 7, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.01, $28,761,141 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: activist-investing, insider-ownership, amendment, closed-end-fund
TL;DR
**Saba Capital updated its stake in abrdn Life Sciences Investors, signaling potential continued activist interest.**
AI Summary
Saba Capital Management, L.P. filed an amended Schedule 13D/A on February 7, 2024, indicating a change in their beneficial ownership of abrdn Life Sciences Investors (formerly TEKLA LIFE SCIENCES INVESTORS). This filing updates previous disclosures regarding Saba Capital's stake in the company. For investors, this matters because Saba Capital is an activist investor, and changes in their holdings or intentions can signal potential future actions, such as pushing for corporate governance changes or a shift in investment strategy, which could impact the stock's value.
Why It Matters
This filing signals an update to Saba Capital's position in abrdn Life Sciences Investors, a closed-end fund often targeted by activist investors seeking to narrow discount to NAV.
Risk Assessment
Risk Level: medium — The presence of an activist investor like Saba Capital can lead to volatility and uncertainty, though it can also drive positive changes.
Analyst Insight
Investors should monitor future filings from Saba Capital for any further changes in their stake or stated intentions, as this could signal a shift in their activist strategy regarding abrdn Life Sciences Investors.
Key Players & Entities
- Saba Capital Management, L.P. (company) — the entity filing the SC 13D/A, an activist investor
- abrdn Life Sciences Investors (company) — the subject company whose securities are being reported
- Boaz R. Weinstein (person) — a group member associated with Saba Capital Management GP, LLC
- Saba Capital Management GP, LLC (company) — a group member associated with the filing
- Michael D'Angelo (person) — contact person for Saba Capital Management, L.P.
FAQ
What is the purpose of this SC 13D/A filing?
This SC 13D/A filing is an amendment (Amendment No. 2) to a previously filed Schedule 13D, updating disclosures regarding Saba Capital Management, L.P.'s beneficial ownership in abrdn Life Sciences Investors, as indicated by the 'Amendment No. 2' notation on the form.
Who is the filer of this SC 13D/A?
The filer of this SC 13D/A is Saba Capital Management, L.P., located at 405 Lexington Avenue, 58th Floor, New York, NY 10174.
What is the subject company of this filing?
The subject company is abrdn Life Sciences Investors, with the CUSIP Number 87911K100 for its Common Shares, $0.01 par value.
When was the event that required this filing?
The date of the event which required the filing of this statement was February 5, 2024.
What was the former name of abrdn Life Sciences Investors?
abrdn Life Sciences Investors was formerly known as TEKLA LIFE SCIENCES INVESTORS, with a name change date of 20141015, and even earlier as H&Q LIFE SCIENCES INVESTORS, with a name change date of 19920929.
Filing Stats: 1,314 words · 5 min read · ~4 pages · Grade level 11.9 · Accepted 2024-02-07 07:55:23
Key Financial Figures
- $0.01 — stors (Name of Issuer) Common Shares, $0.01 par value (Title of Class of Securities
- $28,761,141 — ported herein. A total of approximately $28,761,141 was paid to acquire the Common Shares r
Filing Documents
- formsc13da.htm (SC 13D/A) — 52KB
- 0001062993-24-002124.txt ( ) — 54KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: February 7, 2024 SABA CAPITAL MANAGEMENT, L.P. By: /s/ Michael D'Angelo Name: Michael D'Angelo Title: Chief Compliance Officer SABA CAPITAL MANAGEMENT GP, LLC By: /s/ Michael D'Angelo Name: Michael D'Angelo Title: Authorized Signatory BOAZ R. WEINSTEIN By: /s/ Michael D'Angelo Name: Michael D'Angelo Title: Attorney-in-fact* * Pursuant to a power of attorney dated as of November 16, 2015, which is incorporated herein by reference to Exhibit 2 to the Schedule 13G filed by the Reporting Persons on December 28, 2015, accession number: 0001062993-15-006823 CUSIP No. 87911K100 SCHEDULE 13D/A Page 7 of 7 Pages Schedule A This Schedule sets forth information with respect to each purchase and sale of Common Shares which were effectuated by Saba Capital since the filing of the Schedule 13D/A on 1/12/24. All transactions were effectuated in the open market through a broker. Trade Date Buy/Sell Shares Price 1/16/2024 Buy 52,835 14.12 1/30/2024 Buy 113,928 13.78 1/31/2024 Buy 47,417 13.80 2/1/2024 Buy 4,180 13.89 2/2/2024 Buy 46,540 13.84 2/5/2024 Buy 105,876 13.84 2/6/2024 Buy 86,771 13.94